2-乙酰-3-甲基噻吩 | 13679-72-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-乙酰-3-甲基噻吩
• 中文别名: 2-乙酰基-3-甲基硫代苯；2-乙酰基-3-甲基噻吩
• 英文名称: 2-acetyl-3-methylthiophene
• 英文别名: 3-methyl-2-acetothienone；3-Methyl-2-acetyl-thiophen；3-methyl-thien-2-yl methyl ketone；1-(3-methylthiophen-2-yl)ethanone
• CAS: 13679-72-6
• 化学式: C₇H₈OS
• mdl: MFCD00005443
• 分子量: 140.206
• InChiKey: YBJDKNXEWQSGEL-UHFFFAOYSA-N

物化性质

• 沸点：
  98-99 °C14 mm Hg(lit.)
• 密度：
  1.124 g/mL at 25 °C(lit.)
• 闪点：
  199 °F
• LogP：
  0.683 (est)
• 保留指数：
  1137;1186
• 稳定性/保质期：
  在常温常压下稳定，应避免氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT, IRRITANT-HARMFUL
• 危险品标志：
  Xi
• 危险类别码：
  R20/21/22
• WGK Germany：
  3
• 海关编码：
  2934999090
• 包装等级：
  III
• 安全说明：
  S36/37
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  常温密闭保存，阴凉通风干燥。

反应信息

• 作为反应物：
  描述：

  2-乙酰-3-甲基噻吩 在 sodium methylate 、 溶剂黄146 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 38.0h， 生成 1-methyl-5-(3-methyl-2-thienyl)-3-(trifluoromethyl)-1H-pyrazole
  参考文献：
  名称：

  Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 2: Synthesis and inhibitory activity of aryl-3-trifluoromethylpyrazoles

  摘要：

  To identify potent and selective calcium-release-activated calcium (CRAG) channel inhibitors, we examined the structure-activity relationships of the pyrazole and thiophene moieties in compound 4. Compound 25b was found to exhibit highly potent and selective inhibitory activity for CRAC channels and further modifications of the pyrazole and benzoyl moieties of compound 25b produced compound 29. These compounds were potent inhibitors of IL-2 production in vitro and also acted as inhibitors in pharmacological models of diseases resulting from T-lymphocyte activation, after oral administration. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.03.039
• 作为产物：
  描述：

  1-(3-甲基-2-噻吩基)乙酸乙酯 在 氧气 、 cobalt(II) acetate 、 sodium bromide 作用下， 以 溶剂黄146 为溶剂， 生成 2-乙酰-3-甲基噻吩
  参考文献：
  名称：

  Volkov, M. N.; Kazakova, O. A., Journal of Organic Chemistry USSR (English Translation), 1988, vol. 24, # 2, p. 370 - 373

  摘要：

  DOI：

文献信息

• Asymmetric Hydrogenation of Heteroaromatic Ketones and Cyclic and Acyclic Enones Mediated by Cu(I)-Chiral Diphosphine Catalysts
  作者：Hideo Shimizu、Takashi Ohshima、Kazushi Mashima、Takuto Nagano、Noboru Sayo、Takao Saito

  DOI：10.1055/s-0029-1218347

  日期：2009.12

  Copper(I)-catalyzed asymmetric hydrogenation of heteroaromatic ketones, cyclic and acyclic enones is reported. The choice of the chiral diphosphine ligand highly influenced enantioselectivity as well as chemoselectivity. Highly enantioselective hydrogenation of ortho-substituted heteroaromatic ketones was achieved using BDPP as the ligand. In the 1,2-selective hydrogenation of acylic enone, SEGPHOS

  报道了铜（I）催化的杂芳族酮、环状和无环烯酮的不对称氢化。手性二膦配体的选择极大地影响了对映选择性和化学选择性。使用BDPP作为配体实现了邻位取代的杂芳族酮的高度对映选择性氢化。在酰基烯酮的 1,2-选择性氢化中，SEGPHOS 比 BDPP 具有更高的对映选择性。另一方面，庞大的配体 DTBM-SEGPHOS 具有 1,4-选择性性质，导致环状烯酮的第一个高度 1,4-选择性和对映选择性氢化。
• Antibacterial 3-(5-tetrazolyl)penam compounds
  申请人：Pfizer Inc.

  公开号：US04143039A1

  公开（公告）日：1979-03-06

  Certain novel 6-acylamino-2,2-dimethyl-3-(5-tetrazolyl)penam derivatives, and salts thereof; their use as broad-spectrum antibacterial agents; and methods for their preparation. Their preparation comprises acylation of the novel intermediate, 6-amino-2,2-dimethyl-3-(5-tetrazolyl)penam or simple derivatives thereof, followed, in some cases, by further transformations of the 6-acylamino group or by removal of a protecting group from the 5-tetrazolyl moiety. Process for the preparation of 6-amino-2,2-dimethyl-3-(5-tetrazolyl)penam, simple derivatives thereof and intermediates therefor.

  某些新型6-酰氨基-2,2-二甲基-3-(5-四唑基)佩纳姆衍生物及其盐；它们作为广谱抗菌剂的用途；以及它们的制备方法。它们的制备包括对新型中间体6-氨基-2,2-二甲基-3-(5-四唑基)佩纳姆或其简单衍生物进行酰化，然后，在某些情况下，通过进一步转化6-酰氨基基团或去除5-四唑基团的保护基来进行。制备6-氨基-2,2-二甲基-3-(5-四唑基)佩纳姆、其简单衍生物及其中间体的方法。
• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：Chin Elbert

  公开号：US20100081658A1

  公开（公告）日：2010-04-01

  Compounds having the formula I wherein R 1 , R 2a , R 2b , R 2c , R 3 , Y and p are as defined herein and C2-C3 is a single or double bond are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

  具有以下公式的化合物 I，其中 R1、R2a、R2b、R2c、R3、Y 和 p 的定义如本文所述，且 C2-C3 是单键或双键的化合物是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
• FLUORENE-TYPE COMPOUND, PHOTOPOLYMERIZATION INITIATOR COMPRISING SAID FLUORENE-TYPE COMPOUND, AND PHOTOSENSITIVE COMPOSITION CONTAINING SAID PHOTOPOLYMERIZATION INITIATOR
  申请人：Daito Chemix Corporation

  公开号：US20150259321A1

  公开（公告）日：2015-09-17

  According to an embodiment of the present invention, there is provided a novel fluorene-based compound and a photopolymerization initiator using the fluorene-based compound. The fluorene-based compound according to an embodiment of the present invention is represented by the general formula (1). A photopolymerization initiator having additionally high sensitivity can be provided by using the fluorene-based compound. In addition, a photopolymerization initiator that can impart additionally excellent characteristics can be provided by appropriately selecting, for example, a substituent.

  根据本发明实施例，提供了一种新的基于芴的化合物和使用该基于芴的化合物的光聚合引发剂。根据本发明实施例，基于芴的化合物由通式（1）表示。通过使用基于芴的化合物，可以提供具有更高灵敏度的光聚合引发剂。此外，通过适当选择例如取代基，可以提供具有额外优异特性的光聚合引发剂。
• [EN] ALKYNYL ALCOHOLS AS KINASE INHIBITORS<br/>[FR] ALCOOLS D'ALCYNYLE UTILISÉS COMME INHIBITEURS DE KINASES
  申请人：AMGEN INC

  公开号：WO2009158011A1

  公开（公告）日：2009-12-30

  Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.

  选定的化合物对预防和治疗炎症和炎症性疾病，如NIK介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药及其药用可接受的盐，以及用于预防和治疗涉及炎症等疾病和其他疾病或病症的药物组合物和方法。

表征谱图